FMS-like tyrosine kinase 3 (FLT3) receptor is highly expressed in an array of hematological malignancies including B90% of acute myelogenous leukemia (AML). Ligand stimulation of the receptor promotes the survival and proliferation of leukemia cells. Strategies targeting FLT3 using monoclonal antibodies may therefore constitute an effective therapeutic approach for these leukemia. Towards this, we selected a naïve antibody phage display library on both recombinant FLT3 receptor protein and FLT3-expressing leukemia cells using a tailored selection scheme that was designed to isolate antagonistic phage antibodies that not only interfere with receptor/ligand binding but also trigger receptor internalization upon cell surface binding. Phage antibodies were screened first for their ability to bind to cell surface receptor and induce receptor internalization, followed by their activity in blocking ligandreceptor interaction and neutralizing ligand-stimulated receptor activation and cell proliferation. We identified three fully human antibodies, EB10, A2IN, and D4-3, which bound specifically to both soluble and cell surface-expressed FLT3. All three antibodies were shown to be internalized upon binding to cell surface-expressed receptor in a time-dependent fashion. EB10 and D4-3 blocked ligand binding to the receptor with IC 50 s of 14 and 7 nM, respectively. Further, EB10 and D4-3 inhibited FLT3 ligand-induced receptor phosphorylation and cell proliferation in EOL-1 leukemia cells. Taken together, these results suggest that both EB10 and D4-3 may represent excellent therapeutic candidates for the treatment of FLT3-expressing human leukemia, both as unmodified antibodies and as conjugates of cytotoxic agents.
Introduction
Current standard treatment of acute myeloid leukemia (AML) includes induction of remission with chemotherapies using cytosine arabinoside and anthracycline. Following relapse of the disease, patients are usually treated with additional chemotherapies or stem cell transplantation. 1 This approach is marginally successful, with a 5-year survival rate of 30-40%, and less than 15% in elderly patients. 2 As with other cytotoxic therapies including radiation, these chemotherapeutic agents are usually nonspecific in their mechanisms of action; they often kill normal cells along with the cancer cells, leading to severe systemic toxicities. The ability to direct or deliver therapeutic agents specifically to cancer cells should offer a therapeutic advantage by averting most of the toxicity associated with current therapies. An attractive molecular target for specific delivery of therapeutic agents to leukemia cells is FMS-like tyrosine kinase 3(FLT3), which is expressed at high levels in B90% of AML, B-precursor cell acute lymphoblastic leukemia (ALL), and a smaller portion of chronic myelogenous leukemia in blast crisis. 3, 4 FLT3 is a member of the class III receptor tyrosine kinase family. Upon binding and stimulation by its ligand, FLT3 ligand (FL), the receptor undergoes autophosphorylation in its tyrosine kinase domain, leading to activation of an array of signal transduction molecules and ultimate cell proliferation. [5] [6] [7] FL normally synergizes with other cytokines to stimulate the growth of progenitor cells in the marrow and blood. In leukemia, FL stimulation of FLT3 enhances the proliferation and survival of leukemia blasts. [8] [9] [10] Somatic mutations of FLT3, including internal tandem duplication (ITD) of sequence within the juxtamembrane domain and mutations in the activation loop, have been shown to result in ligand-independent, constitutive activation of the receptor kinase domain and downstream signaling events, confer growth factor independence in leukemia cell lines, and cause a fatal myeloproliferative disorder in mice. [11] [12] [13] Studies have shown that ITD mutations occur in up to 30% of AML patients and activation loop mutations occur in about 7% of AML patients. 13, 14 Patients with these mutations have a lower rate of complete remission and survival, and a poor prognosis. 15, 16 The value of FLT3 as a target for treatment of leukemia has been proven through the development of potent small molecule inhibitors that block the kinase activity of FLT3. [17] [18] [19] [20] However, these small-molecule inhibitors are not completely FLT3 specific as they often recognize other targets such as vascular growth factor receptor 2, platelet-derived growth factor receptor a, and KIT. [17] [18] [19] [20] Owing to their high specificity and affinity towards defined antigens, monoclonal antibodies (mAb) represent a promising class of therapeutics for targeting FLT3-expressing leukemia. The effectiveness of an antibody depends on its capability to induce one or more of several biological mechanisms, including neutralization of ligand/receptor activity, induction of cell apoptosis, mediating of effector cell cytotoxicity, and capability to induce internalization upon binding to cell surface -the latter is particularly critical when the antibody is used as a device to specifically deliver cytotoxic moiety to cancer cells, since the cellular targets of most of the commonly used chemotherapeutics and toxins are intracellularly located. An example for antibody-based drug delivery in conjugate form is Mylotarg s , a conjugate that consists of an internalizing anti-CD33 antibody coupled to a highly potent cytotoxic antibiotic, calicheamicin, which has been approved by the FDA for the treatment of patients aged X60-years-old with relapsed AML. 21 In our previous studies, we produced several ligand-blocking antibodies and demonstrated that these antibodies were capable of neutralizing both ligand-dependent as well as ligand-independent activation of FLT3 and proliferation of leukemia cells, both in vitro and in vivo. 10, 22, 23 In this study, using a leukemia cell-based selection procedure, we identified several fully human antibodies to FLT3 that not only specifically blocked FLT3/FL interaction, but also induced efficient FLT3 receptor internalization upon cell surface binding. In cell-based assays, these antibodies efficiently inhibited FL-induced receptor activation and proliferation of FLT3-expressing leukemia cells. These antibodies represent excellent candidates for the treatment of human FLT þ leukemia, both in unmodified (naked) form or as conjugates to specifically deliver cytotoxic agents to intracellular locations of leukemia cells.
Materials and methods

Cell lines and proteins
The human leukemia cell lines, JM1 (FLT3-negative), EOL-1, and EM3 (both FLT3 þ , wild-type), BaF3/FLT3-ITD (BaF3 cells transfected with a FLT3 ITD mutant), and MV4-11 (FLT3 þ , ITD mutant) were maintained in RPMI 1640 medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% (v/v) fetal bovine serum at 371C in a humidified atmosphere of 5% CO 2 . FLT3-Fc (His), a chimeric protein comprising the extracellular domain of human FLT3 fused to the 6 Â histidine-tagged Fc region of human IgG, and recombinant human FL were purchased from R&D Systems (Minneapolis, MN, USA). IMC-C225, a chimeric IgG1 antibody directed against human epidermal growth factor receptor, was produced at ImClone Systems (New York, NY, USA).
Selection of internalizing anti-FLT3 antibodies from a Fab phage display library
For antigen selection, a large human Fab phage display library containing 3.7 Â 10 10 clones (or colony forming units, CFU) (Dyax Corporation, Cambridge, MA, USA) was used following a previously described procedure. 24 The amplified phage library was first incubated in 3% fat-free milk/PBS containing 1 mg/ml of a human IgG at 371C for 1 h to capture phage displaying antiFc Fab fragments and to block other nonspecific binding. The phage preparation was then transferred to FLT3-Fc-(50 mg/ml) coated Maxisorp Star tubes (Nunc, Rosklide, Denmark) and incubated at room temperature (RT) for 1 h. The tubes were washed 10 times with PBS containing 0.1% Tween-20 and then 10 times with PBS. The bound phage was eluted at RT for 10 min with 1 ml of 10 mM triethylamine (Sigma, St Louis, MO, USA). The eluted phages were incubated with 10 ml of mid-log phase TG1 cells at 371C for 30 min stationary and 30 min shaking. The infected TG1 cells were pelleted and plated onto several large 2YT (per liter: 16 g bacto-tryptone, 10 g bacto-yeast extract, 5 g NaCl, pH 7.0) agar plates supplemented with 100 mg/ml ampicillin and 1% glucose (2YTAG) and incubated overnight at 301C. All the colonies grown on the plates were scraped into 3-5 ml of 2YT medium supplemented with 100 mg/ml ampicillin (2YTA), mixed with 10% glycerol, aliquoted, and stored at -701C. For the second round selection, 100 ml of the bacterial stock was added to 25 ml of 2YTAG medium and grown to midlog phase. The culture was rescued with M13K07 helper phage, amplified, precipitated with PEG, and used for selection following the procedure described above, with reduced concentrations (5 mg/ml) of FLT3-Fc immobilized on the immunotubes and an increased number of washes after the binding process. A total of two rounds of selection on immobilized FLT3-Fc protein were performed.
For selection on FLT3 þ EOL-1 cells, the recovered phage preparation from the two rounds of selection on FLT3-Fc protein was used. Approximately 1.0 Â 10 12 CFU of phage were blocked for 1 h at RT in 1 ml of PBS supplemented with 2% nonfat dry milk and 0.05% Tween-20 (2% MPBST). The blocked phage was then incubated with 9 Â 10 6 JM1 cells (FLT3 negative) in 2 ml of complete RPMI 1640 media for 1 h at 41C to deplete the library of phage particles that bind to nonspecific surface proteins on human leukemia cells. JM1 cells were removed by centrifugation at 500 g for 10 min and the phage supernatant was recovered, followed by incubation with EOL-1 (6.4 Â 10 6 cells for round 1; 2 Â 10 6 for round 2) in 2 ml of complete media at 41C for 1 h. Cells were washed 10 Â in cold media, resuspended in prewarmed complete media and incubated at 371C for 1 h to allow receptor internalization. Noninternalized phages were removed from the cell surface by 10 washes in cold PBS followed by a final wash with glycine buffer (500 mM NaCl, 0.1 M glycine, pH 2.8). After the final wash, the cell pellets were lysed by resuspending in 1 ml of 100 mM triethylamine and rocked at RT for 10 min. The supernatants were removed to a new tube, neutralized with a half volume of 1 M Tris-HCl, pH 7.4, and used to infect 10 ml of a log phase culture of TG1 cells. After centrifugation and resuspension of the TG1 cells in 1 ml of 2YT, 10 ml aliquots were removed for CFU determination, and the rest were plated on two 15-cm 2YTAG plates. A total of two rounds of cell-based selection were performed.
Phage, Fab, and IgG production
Phage from recovered individual clones was prepared and the diversity of these clones was determined as previously described, and further confirmed by nucleotide sequencing. 24, 25 For Fab expression, the DNA sequences encoding Fab from individual clones were amplified by PCR and cloned into the pXP1sacB expression vector (Dyax Corporation). Escherichia coli BL21 Gold cells (Stratagene, La Jolla, CA, USA) were transformed with the Fab-containing expression vectors and plated on LB plates containing 100 mg/ml ampicillin. Expression of Fab in BL21 cells was induced by culturing the bacteria in 2 Â NZCYM-A (per liter: 20 g NZ amine-A, 10 g NaCl, 10 g bacto-yeast extract, 2 g casamino acids, 2 g MgSO 4 , pH 7.5 plus 100 mg/ml ampicillin) containing 100 mM isopropyl-1-thio-b-Dgalactopyranoside (Sigma) at 301C. A periplasmic extract of the cells was prepared and the soluble Fab was purified from the supernatant by affinity chromatography using HiTrap protein G HP columns (Amersham Biosciences, Piscataway, NJ, USA).
To produce the full-length IgG antibodies, the DNA sequences encoding the heavy and the light chain variable genes of each Fab fragment were amplified by PCR and cloned into an expression vector containing the human IgG1 constant domains (Lonza Biologics Inc, Portsmouth, NH, USA). The expression vectors were stably transfected into myeloma NS0 cells, followed by antibody production in serum-free media and purification via Protein A affinity chromatography. The purity of the antibody preparation was analyzed by SDS-PAGE, and the concentration was determined by ELISA, using a rabbit antihuman Fc antibody (Jackson ImmunoResearch Laboratory Inc.) as the capturing agent and horseradish peroxidase (HRP) conjugated goat antihuman k chain antibody (Sigma) as the detection agent. A clinical grade antibody, IMC-C225, was used as the standard for calibration.
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FLT3 binding, FLT3/FL blocking and flow cytometric analysis
Both the FLT3 binding assay and the Flt3/FL blocking assays were carried out following a previously described procedure 22, 24 . For FACS analysis, leukemia cells (5 Â 10 5 /sample) were first incubated for 30 min with a mixture of an anti-CD16 and an anti-CD32 antibody (10 mg/ml, BD Pharmingen, San Diego, CA, USA) in 100 ml cold complete media to block the Fc receptors on the cells. The cells were then incubated at 41C for 1 h with 10 mg/ml of anti-FLT3 antibodies in cold complete media, followed by incubation with 200 ml of a PE-conjugated antihuman k antibody (Sigma) for 45 min at 41C. After washing, the cells were analyzed using a Coulter Epics flow cytometer (Beckman Coulter, Miami, FL, USA).
Antibody internalization assay
Antibodies were radio-iodinated with 125 I using IODO-beads (Pierce Biotechnology, Rockford, IL, USA) according to the manufacturer's instructions. EOL-1 cells were aliquoted into microfuge tubes at 5 Â 10 5 cells/sample in 500 ml cold complete media. Approximately 1 mg of each 125 I-labeled antibody was added to the cells and incubated for 1 h at 41C. Cells were washed 2 Â in cold PBS, resuspended in 500 ml complete media, then incubated at 4 or 371C for 0, 30, 60, 120, 240, or 360 min. At each time point, cells were washed 3 Â in PBS, then the 41C samples were counted on a gamma counter to determine the total amounts of radioactivity bound to the cell surface. The 371C samples were stripped for 5 min with strip buffer (100 mM glycine, 2 M urea, pH 2.5). Both the stripping buffer and stripped cell pellets were then counted on a gamma counter to determine the percentage of radioactivity internalized.
FTL3 phosphorylation assay and cell proliferation assays
The effects of the anti-FLT3 antibodies on the FL-induced (in EOL-1 cells), as well as the ligand-independent (in BaF3/FLT3-ITD cells), FLT3 phosphorylation and cell proliferation were determined following a method previously described. 22 
Results
Selection of internalizing antagonistic anti-FLT3 antibodies
To generate antibodies that bind to and induce internalization of FLT3, phages from a nonimmune human Fab fragment phage library were first selected for two rounds on a soluble FLT3-Fc protein, followed by two further rounds of selection on FLT3-expressing EOL-1 human leukemia cells. After two rounds of selection on immobilized FLT3-Fc protein, approximately 30% of recovered phage clones demonstrated positive binding to the receptor as assayed by ELISA. For cell-based selections, the FLT3-Fc-enriched phage preparation was first depleted of phage clones binding to common cell surface antigens by incubation with FLT3-negative JM1 human leukemia cells. Binding of the library to the FLT3-expressing EOL-1 cells was carried out at 41C, followed by warming to 371C to allow antibody/receptor internalization. Following selection, recovered phage clones were analyzed for binding to both soluble FLT3-Fc and cell surface-expressed receptor, and the ability to block FL/FLT3 interaction.
After two rounds of cell-based selection, the recovered phage clones were tested for their capability to bind recombinant FLT3-Fc by a phage-based ELISA. Out of 92, 13 (14%) randomly picked clones showed positive receptor binding. DNA fingerprint analysis of all positive clones revealed a total of eight unique patterns, which were further confirmed by DNA sequencing. Four of these eight unique clones were also capable of binding to EOL-1 cell surface-expressed FLT3 as assayed by FACS (not shown). Only three clones demonstrated good blocking activity (40-60%) when tested in the FLT3/FL blocking assay (not shown). One of these clones, the dominant clone (representing B40% of all the positive binders in the phage-based ELISA), was EB10, which was also the dominant clone we previously isolated via a selection based entirely on immobilized FLT3 protein. 22 The other two clones were designated as D4-3 and A2IN. These three antibodies were then selected for further studies.
Binding activities of the anti-FLT3 antibodies
Fab fragment and full-length human antibody (IgG1, k) was constructed for all the three anti-FLT3 clones, produced in E. coli and mammalian cells, respectively, and examined for binding to recombinant FLT3 receptor. EB10 Fab showed the strongest binding to the receptor, followed by A2IN Fab and D4-3 Fab (Figure 1a) . When tested as a full-length IgG, D4-3 IgG was the most efficient binder, followed by EB10 IgG and A2IN IgG (Figure 1b) . These results suggest that D4-3 gained the most enhancement in binding avidity upon converting from the monovalent Fab fragment into the bivalent IgG format. None of the three Fab or IgG antibodies bound to normal human IgGcoated plates, indicating they are specific for FLT3. All the three anti-FLT3 IgG also bound to surface-expressed wild-type receptor in EOL-1 and EM3 cells, as well as receptor with ITD mutations in BaF3/FLT3-ITD and MV4-11 cells, as analyzed by FACS (Figure 1c ).
Anti-FLT3 antibodies block FLT3/FL interaction
The ability of purified Fab fragments and full-length IgG to competitively block FLT3/FL interaction was tested in an ELISA (Figure 2 ). D4-3 Fab was the most potent blocker with an IC 50 of B60 nM. EB10 and A2IN Fab also blocked the ligand-receptor binding, with IC 50 s of B250 nM (Figure 2a) . Consistent with the observation in the binding assay (Figure 1b) , D4-3 IgG demonstrated the best blocking efficacy -it blocked the binding of FLT3 to FL with an IC 50 of 7 nM, compared to that of 14 nM for EB10 IgG, and 4100 nM for A2IN IgG (Figure 2b ).
Anti-FLT3 antibodies induce efficient internalization upon binding to cell surface receptor
The ability of EB10, A2IN, and D4-3 IgG to induce receptor internalization upon binding to the cell surface was investigated in EOL-1 cells using radiolabeled antibodies. EOL-1 cells were first incubated with radiolabeled antibodies at 41C, and transferred to 371C to allow receptor internalization to occur. At predefined intervals, aliquots of EOL-1 cells were washed in low pH buffer to remove surface-bound radioactivity, followed by the determination of radioactivity internalized. As expected, all three radiolabeled antibody preparations bound specifically to EOL-1 cells at 41C. When the cells were incubated at 371C all three antibodies showed efficient internalization in a timedependent fashion, with maximum amount of internalization, between B45-70% of cell-bound radioactivity, reached at about 1-4 h of incubation (Table 1) . These results are in good agreement with those observed in the phage-based internalization assay (not shown).
Anti-FLT3 antibodies inhibit FL-induced phosphorylation of FLT3 in leukemia cells
We next tested whether the anti-FLT3 antibodies would inhibit FLT3 receptor phosphorylation in EOL-1 (wild-type FLT3) and BaF3/FLT3-ITD leukemia cells. Treatment with FL results in strong FLT3 receptor phosphorylation in EOL-1 cells (Figure 3a) , which was significantly (85-90%) inhibited by D4-3 and EB10 (Figure 3a) . In BaF3/FLT3-ITD cells, FLT3 is constitutively phosphorylated in the absence of FL (Figure 3b) . Treatment with the anti-FLT3 antibodies inhibited the activation of the receptor only marginally to modestly. At 15 nM antibody concentration, D4-3 and EB10 yielded B36 and 26% inhibition in receptor phosphorylation, respectively (Figure 3b ). In both cell lines, A2IN IgG failed to significantly inhibit receptor activation. This is in good agreement with the observation (Figure 2 ) that A2IN only marginally blocked FLT3/FL interaction (B25%) at the highest antibody concentration used in the assay (15 nM). As expected, IMC-C225 did not showed any effect on FLT3 phosphorylation.
Anti-FLT3 antibodies inhibit FL-induced proliferation of human leukemia cells
Since our anti-FLT3 antibodies are capable of blocking FLT3/FL interaction and inducing receptor internalization, we next investigated whether these antibodies can also inhibit FL-induced The control antibody, IMC-C225, had no effect on ligandinduced proliferation of EOL-1 cells. Both D4-3 and EB10, at the maximum antibody concentration (400 nM) used in the study, had only marginal inhibitory activity (5-15%) to ligandindependent growth of BaF3/FLT3-ITD cells (data not shown).
Discussion
Here we described an efficient cell-based selection procedure for the identification from a phage display library of anti-FLT3 antibodies that not only block receptor-ligand interaction effectively but also trigger efficient receptor internalization upon cell surface binding. In this procedure, we first isolated a number of internalizing anti-FLT3 antibodies by panning the phage display library against both recombinant FLT3 protein and leukemia cells expressing the receptor, following a scheme that was designed to isolate phage-displayed antibodies that are internalized upon binding to cell surface-expressed receptor. Upon further examination for their capability in blocking FLT3/FL interaction, three antibodies with the ideal characteristics were identified. All the three antibodies, EB10, A2IN, and D4-3, bind specifically to FLT3, block FLT3/FL interaction, and are effectively internalized upon binding to leukemia cell surface-expressed receptor. Further, EB10 and D4-3, were also efficacious in inhibiting FL-stimulated receptor phosphorylation and proliferation of human leukemia cells. We believe the cellbased antibody selection procedure we described here is applicable to the identification from antibody libraries of internalizing antibodies to other cell surface targets.
FLT3 constitutes an attractive target for leukemia therapy due to its important role in the survival and proliferation of leukemia cells, and its overexpression and mutation in a high percentage of AML and ALL patients. To date, several FLT3-selective small molecule inhibitors have been identified and have demonstrated potent antileukemia activity in a number of animal models, including indolocarbazole derivative CEP-701, 18 N-benzoylstaurosporine (PKC412), 20 CT53518, 17 and SU11248. 19 Some of these compounds are being evaluated in various stages of clinical trials in AML patients. Most of these kinase inhibitors are not truly FLT3-specific as they also target other kinases such as high-affinity nerve growth factor receptors, 18 protein kinase C, a EOL-1 cells were incubated with the radiolabeled antibodies at 41C for 1 h, and transferred to 371C to allow receptor internalization. At predefined intervals, cells were washed with ice-cold PBS and surface-bound antibody was stripped with a low pH buffer. Radioactivity in the stripping buffer and those remained associated with the cell pellets was counted. The percentage of internalization was calculated by: cell pelletassociated radioactivity/cell pellet-associated radioactivity+radioactiv-ity in the stripping buffer. Data are the mean of two separate experiments.
Selection of antagonistic human antibodies to FLT3 B Williams et al evaluate the contribution of FLT3 inhibition in the overall antitumor activity of these compounds. Potential systemic toxicity may also be an issue for these small molecular inhibitors due to their broad target profile. To this end, an antagonistic anti-FLT3 antibody may prove to be advantageous because of its high binding affinity and exquisite specificity. mAb are being developed as cancer therapeutics both as unmodified (naked) form and as conjugates to other cytotoxic moieties. Eight antibody-based products have been approved so far by the FDA, including five naked (unmodified) mAb and three antibody conjugates, for the treatment of several human cancers. The effectiveness of a naked antibody depends on its capability to induce one or more of several biological mechanisms, including (1) direct antitumor activity via blockade of growth factor/receptor interaction (leading to inhibition of receptor activation and cell proliferation), modulation (downregulation) of receptor surface expression, and/or induction directly or indirectly of apoptosis; (2) recruiting effector mechanisms of the immune system, such as the antibodydependent cellular cytotoxicity (ADCC) and complementmediated cytotoxicity (CMC); (3) stimulating the antiidiotype network to generate antitumor anti-anti-idiotypic antibody response; and (4) potentiating the cytotoxic effects of other therapeutic agents such as chemotherapeutic drugs and radiation. In this study, we tailored a selection procedure in an attempt to both directly and specifically identify antibodies that not only block growth factor/receptor interaction but also trigger efficient receptor internalization. Three antibody candidates with proper (predefined) properties were identified from a naïve antibody phage display library, highlighting the success of our selection approach. The antibody leads were further engineered into a human IgG1 format, thus conferring their capability of mediating ADCC and CMC activities under proper circumstances. For example, EB10 IgG was shown to be capable of mediating efficient ADCC toward FLT3 þ leukemia cells in the presence of human effector cells. 23 While both EB10 and D4-3 demonstrated strong inhibitory effects on FL-induced FLT3 phosphorylation and cell proliferation in leukemia cells harboring the wild-type receptor, the antibodies were much less efficacious towards leukemia cells expressing FLT3-ITD mutant receptor (Figures 3 and 4 ; and Li et al 22 ) . Thus, it was very intriguing to note that, when administered in vivo, EB10 significantly prolonged not only the survival of mice inoculated with EOL-1 cells, but also that of mice challenged with BaF3/ FLT3-ITD cells. 22 Further, EB10 was also very effective in inhibiting the engraftment in nonobese diabetic/severe combined immunodeficient mice of human primary leukemia cells expressing FLT3-ITD mutants. 23 Taken together, these data suggest that, apart from the direct FLT3/FL blockade, the anti-FLT3 antibodies may also exert their antitumor activity via other Inhibition of FL-stimulated proliferation of EOL-1 cells by the anti-FLT3 antibodies. Cells were cultured in AIM-V medium for 68 h, with varying concentrations of antibodies (from 0 to 400 nM) in the presence of exogenous FL (30 ng/ml). In a background control, EOL-1cells were incubated with medium alone in the absence of exogenous FL. Cells were pulsed for 4 h with 3 H-thymidine, harvested, and cpm measured by a beta scintillation counter. The percent of FLinduced EOL-1 cell growth inhibition was calculated using the following formula: In addition to their use in unmodified forms, mAb are also being utilized as targeting devices to specifically deliver cytotoxic agents to tumor sites in conjugated forms. Several classes of cytotoxic agents, including chemotherapeutic agents and toxins, have been conjugated to antitumor mAb and tested both preclinically and in various clinical studies. One of the most important aspects in the preparation of an efficacious conjugate is the selection of an appropriate mAb to be used as the carrier of the cytotoxic agent, which may be heavily dependent on the intended use of the conjugate, as well as the natural properties of the cytotoxic moiety and its mode of action. Most chemotherapeutic agents and toxins require internalization to exert their cytotoxic effects since the cellular targets of these agents are usually intracellularly located. It is, therefore, critical to choose a mAb that would induce significant internalization upon cell surface binding to allow maximum delivery of the conjugated cytotoxic agents into the intracellular compartment. Here, by using a tailored selection procedure, we identified 3 mAb that efficiently internalize upon binding to FLT3 on the leukemia cell surface. These mAb thus represent excellent candidates for the construction of efficacious cytotoxic conjugates for the targeting of FLT3 (both wild type and mutants)-expressing human leukemia.
In conclusion, we identified from a phage display library, via a tailored cell-based selection procedure, three fully human antagonistic anti-FLT3 antibodies based on their capability in blocking receptor/ligand interaction and triggering efficient receptor internalization. Taken together with our previous observation, 22, 23 these results lend strong support to the further development of these antibodies as potential therapeutics for human leukemia.
